Diagnostic Criteria and Therapeutic Approach in Patients with Pediatric Dyslipidemia
DOI:
https://doi.org/10.53089/medula.v12i4.481Keywords:
atherosclerosis, diagnostic, pediatric, therapeutic approachAbstract
Dyslipidemia or hyperlipoproteinemia is a quantitative change in the concentration of total cholesterol, its fraction, or just triglycerides in plasma. In addition, there is ample evidence to support that pediatric dyslipidemia is associated with atherosclerosis in adulthood. To reduce cardiovascular risk in adulthood, early identification and treatment is needed to reduce morbidity and mortality. Dyslipidemia itself can occur due to changes in primary lipoprotein metabolism due to genetic (primary) causes or other pathologies such as the result of accumulation of exogenous (secondary) factors. Therefore, mixed dyslipidemia results from genetic and environmental associations with risk factors for cardiovascular disease. However, lipid metabolism screening in pediatrics is not carried out in a targeted manner, causing problems where the outcome is not generally accepted. In addition, no one knows the effect of long-term pharmacological therapy. Therefore, this study aimed to review the various available literature resources on pediatric dyslipidemia to present data on a structured approach to pediatric dyslipidemia that focuses on screening, atherosclerotic risk stratification, and therapeutic approaches.
References
de Ferranti SD, Newburger JW. Dyslipidemia in children and adolescents: Definition, screening, and diagnosis. UpToDate. USA: Wolters Kluwer. 2020.
Correia-Costa A, Correia-Costa L, Caldas Afonso A, Schaefer F, Guerra A, Moura C, Mota C, Barros H, Areias JC dan Azevedo A. Determinants of carotid-femoral pulse wave velocity in prepubertal children. International journal of cardiology, 2016;218:37–42. https://doi.org/10.1016/j.ijcard.2016.05.060.
de Henauw S, Michels N, Vyncke K, Hebestreit A, Russo P, Intemann T, Peplies J, Fraterman A, Eiben G, de Lorgeril M, Tornaritis M, Molnar D, Veidebaum T, Ahrens W, Moreno LA. Blood lipids among young children in Europe: results from the European IDEFICS study. International journal of obesity.2014;38:Suppl 2, S67–S75.https://doi.org/10.1038/ijo.2014.137
di Bonito P, Valerio G, Grugni G, Licenziati MR, Maffeis C, Manco M, Miraglia del Giudice E, Pacifico L, Pellegrin MC, Tomat M, Baroni MG. Cardiometabolic risk factors in overweight and obese children in ITALY (CARITALY) Study Group. Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. Nutrition, metabolism, and cardiovascular diseases: NMCD.2015;25 (5):489494.https://doi.org/10.1016/j.numecd.2015.01.012
Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV, dan Chiesa C. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutrition, metabolism, and cardiovascular diseases: NMCD.2014;24(7):737–743. https://doi.org/10.1016/j.numecd.2014.01.010
Spinneker A, Egert S, González-Gross M, Breidenassel C, Albers U, Stoffel-Wagner B, Huybrechts I, Manios Y, Venneria E, Molnar D, Widhalm K, Moreno L., Stehle P, dan HELENA Study Group. Lipid, lipoprotein and apolipoprotein profiles in European adolescents and its associations with gender, biological maturity and body fat--the HELENA Study. European journal of clinical nutrition. 2012;66(6):727–735. https://doi.org/10.1038/ejcn.2011.222
Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, dan Ward AM. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ (Clinical research ed.),2012; 345:e4759.https://doi.org/10.1136/bmj.e4759
Zschocke J. Disorders of the biosynthesis and breakdown of complex molecules in Inherited Metabolic Diseases. Berlin, Germany: Springer. 2017.
Hoffmann GF, Zschocke J, dan Nyhan WL. Inherited Metabolic Diseases-A Clinical Approach. Berlin: Springer.2017.
Kliegman RM, Stanton BF, St Geme III J, Joseph W, dan Schor NF. Nelson Textbook of Pediatrics: Disorders of lipoprotein metabolism and transport. Edisi XX. Netherlands: Elsevier. 2017.
Saudubray JM, Baumgartner MR, dan Walter J. Inborn Metabolic Diseases. Berlin: Springer. 2016.
Patni N, Ahmad Z, dan Wilson DP. Genetics and Dyslipidemia. MA: Dartmouth. 2020.
Stewart J, McCallin T, Martinez J, Chacko S, dan Yusuf S. Hyperlipidemia. Pediatrics in Review. 2002;41(8): 393–402.
Elkins C, Fruh S, Jones L, dan Bydalek K. Clinical practice recommendations for pediatric dyslipidemia, Journal of Pediatric Health Care. 2019;33(4):494–504.
Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia, Journal of the American College of Cardiology.2012;72 (6): 662–680.
de Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 (5): 213–56.
Berberich AJ dan Hegele RA. +e complex molecular genetics of familial hypercholesterolaemia. Nature Reviews Cardiology. 2019;16 (1): 9–20.
de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American heart association. Circulation. 2019;139: 603–34.
Bibbins-Domingo B, Grossman DC, Curry SJ, et al. Screening for lipid disorders in children and adolescents US preventive services task force recommendation statement. JAMA. 2016;316 (6): 625–33.
de Ferranti SD, Jane N. Dyslipidemia in Children: Definition, screening, and diagnosis. UpToDate. USA: Wolters Kluwer. 2016.
Elmaogullari S, Tepe D, Uçakturk SA, Kara FK, dan Demirel F. Prevalence of dyslipidemia and associated factors in obese children and adolescents,” Journal of Clinical Research in Pediatric Endocrinology. 2015; 7 (3): 228–34.
Drozdz D, Alvarez-Pitti J, W´ojcik M, et al. Obesity and cardiometabolic risk factors: from childhood to adulthood. Nutrients. 2021, 13 (11): 1–20.
Hegele RA dan Tonstad S. Disorders of lipoprotein metabolism. Dalam: Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Berlin: Springer; 2014: 671–89.
Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019; 139 (25).
Sa´ude DG de, Portugal, Programa nacional de sa´ude infantil e juvenil. 2013.
Guerrero-Fdez J, Cart´on S´anches A, Bonis AB, Suso JM, dan Dominguez JR. Manual de Diagn´ostico y Terapˆeutica en Pediatria. Edisi VIa, Editorial M´edica Panamericana, S.A., Madrid, Spain, 2018.
Gudbjartsson DF, Thorgeirsson G, Sulem P., et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes,” Journal of the American College of Cardiology. 2019; 74 (24): 2982–2994.
Alves AC, Sequeira S, Moldovan O, et al. Estudo de dislipidemias familiares monog´enicas raras. Boletim Epidemiol´ogico. 2016, 5: 52–56.
Burton BK, Deegan PB, Enns GM, et al. Clinical features of lysosomal acid lipase deficiency. Journal of Pediatric Gastroenterology & Nutrition. 2015; 61(6): 619–625.
Fiorentino R dan Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021; 9(9).
Bianchini JAA, da Silva DF, Nardo CCS, Carolino IDR, Hernandes F, dan Junior NN. Multidisciplinary therapy reduces risk factors for metabolic syndrome in obese adolescents. European Journal of Pediatrics, 2013; 172 (2): 215–221.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
